Stock Option Expensing: What It Is and Why Grant-Date Valuation Is the Foundation
Published on 29 Jun, 2026
When a company grants stock options to employees, it incurs a compensation cost that must be measured and recognized in its financial statements. The starting point for that measurement is the fair value of the option on the date it is granted, a number that requires specialist valuation expertise to determine correctly.
What is stock option expensing?
Stock option expensing is the process by which companies recognise the cost of equity-based compensation in their financial statements. Under ASC 718 (US GAAP) and IFRS 2 (international standards), companies are required to measure the fair value of stock options and other equity awards at the grant date and recognise that value as compensation expense over the period during which employees earn the award.
The requirement to expense stock options reflects a straightforward economic reality: when a company grants an employee the right to buy shares at today's price at some point in the future, it is providing something of value. That value is a cost to the company, and accounting standards require it to be reflected in the financial statements just as cash compensation would be.
The valuation component of stock option expensing is the grant-date fair value. Everything else in the expensing process flows from that single number. If the grant-date fair value is incorrectly determined, the compensation expense recognised over the vesting period will be wrong, which creates audit exposure; financial restatement risk and in public company contexts; potential regulatory consequences.
The valuation is the foundation. Stock option expensing involves both a valuation step and an accounting step. The valuation step is determining the grant-date fair value through the work of a credentialed independent appraiser. The accounting step is recognizing that value as expense over the vesting period which is the work of the company's finance team and auditors. This series focuses on the valuation step.
The 409A FMV and the ASC 718 fair value: two different valuations of the same option
Companies that grant stock options typically obtain two separate valuations: a 409A valuation and an ASC 718 fair value. These are related but distinct exercises, and confusing them is one of the most common errors in startup equity practice.
The 409A valuation establishes the fair market value of the underlying common stock i.e. the number used to set the option strike price. The ASC 718 fair value measures the fair value of the option itself i.e. the right to buy that stock at the strike price over the option's life. The two valuations use different methodologies, serve different purposes, and produce different numbers.
409A VALUATIONCommon Stock Fair Market Value |
ASC 718 FAIR VALUEOption grant-date fair value |
|
|---|---|---|
| Purpose | Sets the option strike price under IRC §409A. | Measures compensation expense under ASC 718 or IFRS 2. |
| What is valued | A share of common stock in the company. | The option itself, i.e. the right to buy stock at the strike price. |
| Primary methodology | Income approach (DCF), market approach (comparable companies), and asset approach followed by OPM or PWERM to allocate value to common stock. | Black-Scholes, Binomial, or Monte Carlo model. |
| Standard | Treasury Regulations §1.409A-1(b)(5)(iv) | ASC 718 / IFRS 2 |
| Frequency | At least annually or after material events. | At each grant date. |
| Output | FMV per share of common stock. | Fair value per option granted. |
The two valuations are connected since the 409A FMV feeds into the ASC 718 model as the current stock price input but they are not interchangeable. Using the 409A FMV as a proxy for the ASC 718 fair value is a methodological error that produces an incorrect compensation expense figure. For a detailed treatment of how the two valuations interact, see 409A Valuation and Stock Option Expensing: How the Two Valuations Differ and Interact.
What the grant-date fair value captures: Key inputs and why they require specialist expertise
The grant-date fair value of a stock option reflects the economic value of the right to buy a share at the strike price at some point in the future, measured at the moment the option is granted. That value is determined by several inputs, each of which requires careful derivation particularly for private companies whose shares are not traded on a public market.
Current stock price
The fair market value of the underlying share at the grant date which is typically derived from the most recent 409A valuation.
Why it requires expertise: for private companies this is not observable and must be independently determined
Exercise price
The strike price at which the option holder can buy shares. This is set at or above the 409A FMV to comply with §409A.
Why it requires expertise: must be consistent with a contemporaneous 409A valuation to be defensible
Expected volatility
The expected variability of the underlying stock's returns over the option's life. The most sensitive input in the valuation model for most grants.
Why it requires expertise: private companies have no traded volatility; it must be derived from comparable public company data
Expected term
The expected period from grant date to exercise. Shorter than the contractual term because employees typically exercise before expiry.
Why it requires expertise: must be estimated from historical exercise patterns or the simplified method for first-time grants
Risk-free rate
The return on a risk-free investment over the expected term of the option — typically derived from government bond yields.
Expected dividend yield: the maturity must match the expected term, not the contractual term
Risk-free rate
The expected dividend payments over the option's life as a percentage of the stock price. For most pre-revenue companies this is zero.
Why it requires expertise: for companies approaching profitability, dividend assumptions require explicit documentation
Expected volatility is the most consequential input. For private companies, expected volatility cannot be observed directly and must be estimated from the historical stock price volatility of comparable publicly traded companies. The selection of the peer group, the measurement period, and the adjustment for leverage differences all require professional judgment. Errors in volatility estimation flow directly and proportionally into errors in the grant-date fair value and therefore into the compensation expense recognized over the vesting period. For a full treatment of assumption derivation, see Key Assumptions in Stock Option Valuation.
Types of share-based compensation and their valuation characteristics
ASC 718 and IFRS 2 apply to a broad range of equity-linked compensation instruments, not only standard stock options. Each instrument type has distinct valuation characteristics that affect the methodology used to determine grant-date fair value.
| INSTRUMENT | VALUATION CHARACTERISTIC | PRIMARY VALUATION METHODOLOGY |
|---|---|---|
| Stock options | Value depends on the spread between stock price and strike price and the optionality of the right to buy. | Black-Scholes or binomial model using the six inputs described above. |
| Restricted stock units (RSUs) | Value is simply the fair value of the underlying share at grant — no optionality, no strike price. | Underlying stock price at grant date. For dividend-paying companies, adjusted downward by the present value of expected dividends not received during the vesting period. For non-dividend paying companies, no adjustment is required. |
| Performance awards with market conditions | Value depends on achieving a market-based target such as a total shareholder return or share price threshold. This must be modelled across a distribution of outcomes. | Monte Carlo simulation to capture the probability distribution of the market condition being met. |
| Employee stock purchase plans (ESPPs) | Value derives from the discount and the lookback feature — the right to buy at a discount to the lower of the price at the beginning or end of the offering period | Black-Scholes applied to the components of the ESPP discount and lookback feature separately. |
| Stock appreciation rights (SARs) | Similar payoff to stock options but settled in cash — which creates a liability that must be remeasured at each reporting date, not only at grant | Option pricing model at grant date and at each subsequent remeasurement date |
For a detailed treatment of how stock options and RSUs differ in valuation approach and what drives the difference in concluded values, see Stock Options vs RSUs: Valuation Differences and What Drives Them. For performance awards specifically, see Valuing Performance-Based Stock Awards: How Performance Conditions Affect Fair Value.
Why independent valuation is required
For publicly traded companies, the current stock price is observable and the volatility can be derived directly from the company's own trading history. The grant-date fair value can be determined with relatively straightforward model application.
For private companies, which includes the majority of venture-backed startups, pre-IPO companies, and subsidiary entities, neither the stock price nor the volatility is directly observable. Both must be determined through independent professional analysis. An internal estimate produced by the company's finance team does not meet the standard required by auditors for two reasons: it lacks independence, and it typically lacks the methodological rigour required to support the input derivation.
Auditors assess the grant-date fair value as part of the stock-based compensation review in every financial statement audit. Where the valuation cannot be supported by documented, independently derived inputs, the auditor will either require the company to obtain an
Using the 409A FMV as the ASC 718 fair value is not acceptable. The 409A establishes the fair market value of a share of common stock. The ASC 718 fair value measures the value of the option — which includes the time value of the right to buy that stock in the future. The two numbers are different by construction. Substituting one for the other produces a compensation expense figure that is systematically too low and will be challenged by auditors. For more on common valuation mistakes, see Common Stock Option Valuation Mistakes and How to Avoid Them.
independent valuation or will challenge the expense figure — both of which are disruptive outcomes that are more costly than commissioning the valuation in the first place.
When the valuation obligation arises
The grant-date fair value must be determined at the time each grant is made, not retrospectively. The obligation arises at every grant cycle, including:
New hire grants
— every option grant to a new employee requires a contemporaneous grant-date fair value. Where grants are made frequently, many companies commission valuations on a quarterly or semi-annual cycle to cover all grants within a defined periodAnnual refresh grants
— periodic top-up grants to existing employees require the same grant-date fair value treatment as initial grantsModified awards
— where the terms of existing awards are modified — including repricing, vesting acceleration, or extension of the exercise period — the modification triggers an incremental fair value measurement that requires the same valuation methodology as a new grantPerformance award grants
— awards with market conditions require grant-date fair value measurement using Monte Carlo simulation, which is a distinct exercise from standard option pricing and typically requires specialist inputPre-IPO and M&A contexts
— companies preparing for an IPO or a sale face heightened scrutiny of their historical stock-based compensation expense. Every grant in the lookback period must be supported by a contemporaneous, independently derived grant-date fair value. For more on the M&A context specifically, see Stock Option Valuation in M&A Transactions: How Unvested Awards Are Valued
Key Takeaways
- Stock option expensing requires companies to measure the fair value of equity awards at the grant date and recognize that value as compensation expense — the grant-date fair value is the foundation of the entire exercise
- The 409A valuation and the ASC 718 fair value are two distinct valuations — the 409A establishes the common stock FMV used to set the strike price; the ASC 718 fair value measures the value of the option itself using an option pricing model
- Expected volatility is the most consequential input for private companies — it cannot be observed directly and must be derived from comparable public company data using professional judgment
- Different equity compensation instruments require different valuation approaches — RSUs are valued at the underlying stock price, standard options use Black-Scholes or binomial models, and performance awards with market conditions require Monte Carlo simulation
- For private companies, independent valuation of the grant-date fair value is required — internal estimates lack the independence and methodological rigor required by auditors
- The valuation obligation arises at every grant date, at award modifications, and is subject to heightened scrutiny in pre-IPO and M&A contexts
Frequently asked questions
What is stock option expensing?
Stock option expensing is the process by which companies measure and recognise the cost of equity-based compensation in their financial statements. Under ASC 718 (US GAAP) and IFRS 2 (international standards), the cost is measured at the grant-date fair value of the award and recognised as expense over the vesting period.
What is the difference between a 409A valuation and an ASC 718 fair value?
A 409A valuation determines the fair market value of a share of common stock—used to set the option strike price. An ASC 718 fair value measures the fair value of the option itself—the right to buy that stock at the strike price over the option's life. The two use different methodologies and produce different numbers. The 409A feeds into the ASC 718 model as an input but cannot substitute for it.
Why do private companies need an independent stock option valuation?
For private companies, neither the current stock price nor the expected volatility is directly observable; both must be independently determined. Auditors require that the grant-date fair value be supported by documented, independently derived inputs. Internal estimates lack the independence and methodological rigour required to meet that standard.
How often does the grant-date fair value need to be determined?
The grant-date fair value must be determined at each grant date. Companies that grant options frequently typically commission valuations on a quarterly or semi-annual cycle. Award modifications, including repricing and vesting acceleration, also trigger a new fair value measurement. Pre-IPO and M&A contexts require particular attention to the completeness of the historical grant-date fair value record.
Related Reading in This Series
- How to Value Employee Stock Options
- Key Assumptions in Stock Option Valuation
- Common Stock Option Valuation Mistakes and How to Avoid Them
- When Do You Need an Independent Stock Option Valuation?
This article is part of a series on stock option expensing and is intended for general informational purposes only. It does not constitute legal, tax, financial, or accounting advice. The descriptions of ASC 718 and IFRS 2 requirements presented here focus on the valuation implications and are not a comprehensive treatment of either standard. Both standards are subject to amendment and interpretation. Companies should obtain qualified auditors and a credentialed independent valuation professional for any stock option valuation engagement. This article does not create an attorney-client or appraiser-client relationship.